The Current Asthma Research Landscape
Asthma affects more than 25 million people in the United States, and for a significant portion, standard treatments leave gaps that impact daily life. The American Lung Association runs the Airways Clinical Research Centers network, which spans multiple states and focuses on patient-centered asthma studies. This is not research happening in distant labs—it is happening in clinics across Arizona, Illinois, New York, North Carolina, and Vermont, often with direct involvement from the people who live in those communities.
In April 2026, Breztri Aerosphere received approval in the US as the first triple-combination therapy for asthma in patients 12 and older. That decision came directly out of the KALOS and LOGOS Phase III trials, where researchers demonstrated that a single inhaler combining three medications could outperform standard dual therapies. Stories like this are why many patients begin exploring "asthma clinical trials near me"—not just for personal benefit, but because trial participants quite literally shape the future of asthma care.
Meanwhile, biologic therapies continue to expand. In late 2025, EXDENSUR (depemokimab) was approved as an add-on maintenance treatment for severe eosinophilic asthma, given as an injection once every six months. The clinical trials behind this approval enrolled 762 patients across 331 sites worldwide, with a quarter of those participants coming from the United States. For someone with severe asthma who struggles with daily inhaler routines, a twice-yearly injection represents a meaningful shift in how treatment fits into daily life.
Types of Asthma Trials and What They Test
Asthma clinical trials vary considerably in what they aim to achieve. Understanding the different categories helps in deciding which ones might be worth pursuing, especially when searching for "severe asthma clinical trials" that target specific inflammatory pathways.
| Trial Type | What It Tests | Typical Duration | Best For | Considerations |
|---|
| Phase III inhaled therapies | New inhalers or combinations against existing treatments | 24–52 weeks | Patients with moderate asthma on current therapy | May require frequent clinic visits for lung function tests |
| Biologic trials | Injectable medications targeting specific inflammatory pathways | 6–12 months | Severe eosinophilic or allergic asthma patients | Often requires blood eosinophil counts above a certain threshold |
| Step-down studies | Whether patients on biologics can safely reduce other medications | 12–24 months | Patients stable on biologic therapy | Goal is medication reduction while maintaining control |
| Lifestyle intervention trials | Weight management, breathing techniques, or environmental modifications | 3–6 months | Patients with obesity-related asthma or environmental triggers | Less medication-focused; more behavioral |
| Pediatric-specific trials | Safety and dosing in children and adolescents | Varies | Children aged 6–17 with diagnosed asthma | Parental consent and child assent required |
Beyond these categories, some trials focus on specific populations with overlapping conditions. The TRIM study (Trial of Roflumilast in Asthma Management), currently recruiting through the ALA ACRC network, specifically looks at adults with poorly controlled asthma and elevated BMI. This kind of targeted research matters because asthma does not behave the same way in every body, and treatments that work for one group may underperform in another. If you are exploring "asthma research studies enrolling" in your area, knowing which subtype of asthma you have—allergic, eosinophilic, or obesity-related—can point you toward the most relevant options.
The investigational pipeline also includes novel combinations. One Phase III study is evaluating a fixed-dose combination of fluticasone propionate and albuterol sulfate delivered via an electronic multidose dry powder inhaler. The study design spans a minimum of 28 weeks and includes a run-in period to establish baseline asthma control before randomization. These electronic inhalers track each use, giving researchers insight into adherence patterns that traditional trials might miss.
Finding the Right Trial and Navigating Eligibility
The sheer volume of asthma studies listed on ClinicalTrials.gov can overwhelm anyone. Typing "asthma clinical trials near me" into a search engine usually leads there, but the database contains thousands of entries, not all of which are actively recruiting. Narrowing things down requires a bit of strategy.
Start with the American Lung Association's clinical trial finder. It curates trials from the ACRC network specifically, which means the studies are vetted and actively recruiting at US-based centers. The locations are concrete: University of Arizona in Tucson, Northwestern in Chicago, Mount Sinai in New York, Duke in North Carolina, and the Vermont Lung Center. These are academic medical centers with dedicated research coordinators who can walk potential participants through the "asthma clinical trial eligibility criteria" step by step.
Each trial has an inclusion and exclusion criteria list. Common requirements for asthma trials include a documented diagnosis for at least 12 months, a certain level of lung function measured by FEV1 (forced expiratory volume in one second), and stability on current medications for a defined period before enrollment. Some biologic trials require blood tests showing elevated eosinophil counts, while others may look for specific allergic markers. The screening process often involves multiple visits before a participant is officially enrolled.
Sarah, a 38-year-old teacher in Phoenix, spent nearly two years on a waiting list for a biologic trial after her severe asthma kept landing her in the emergency department. "I had tried every inhaler my doctor prescribed, and oral steroids were becoming a monthly necessity," she recalls. Her local research center eventually matched her with a study testing a new anti-IL-5 therapy. The screening process involved blood work, lung function tests, and a detailed medical history review. Within three months of starting the trial medication, her exacerbations dropped significantly. Stories like Sarah's are not uncommon—many participants in "asthma biologic clinical trials" report improvements that their previous regimens never achieved.
What Participation Actually Looks Like
Enrolling in a clinical trial is not a casual commitment. Most asthma studies require regular site visits—sometimes weekly during the initial phase, then tapering to monthly or quarterly. At each visit, participants typically undergo spirometry testing, complete symptom questionnaires, and meet with the study team to review any changes in their condition.
The screening period alone can last two to four weeks. During this time, researchers establish baseline measurements and confirm eligibility. Some trials use a run-in period where participants continue their usual medications while the team monitors asthma control. This helps determine whether the asthma is truly uncontrolled before introducing the experimental treatment. For those considering "paid asthma clinical trials," it is worth noting that the time commitment often extends well beyond the initial visits.
The TAPER study, a Phase 3b trial exploring whether patients on tezepelumab can safely reduce background medications, illustrates the extended timeline: up to 52 weeks of participation with multiple site visits and careful monitoring. That is a substantial time investment, but for patients whose asthma has been difficult to manage, the opportunity to access cutting-edge treatment while contributing to medical knowledge carries real weight.
The financial side varies between studies. Most trials cover the cost of the investigational medication and study-related procedures. Some also provide reimbursement for travel expenses and time, though amounts differ widely between institutions. The informed consent document spells out exactly what is covered and what is not, and it is worth reading thoroughly before signing. Research coordinators can clarify whether parking, public transit, or mileage is reimbursed. Some trials also offer flexible scheduling for working participants, including early morning or evening visit slots.
Insurance interaction is another consideration. Routine asthma care typically continues through the participant's regular insurance during a trial, while study-specific procedures fall under the trial sponsor's budget. Clarifying this boundary early prevents unexpected bills later.
Regional Resources and Next Steps
Access to asthma trials varies by geography. Major metropolitan areas with academic medical centers—Boston, New York, Chicago, Los Angeles, San Francisco, Houston, Durham, and Seattle—tend to have the most active research programs. The National Institutes of Health Clinical Center in Bethesda, Maryland, also runs asthma studies and accepts participants from across the country. For those in rural areas, some trials now incorporate telehealth visits to reduce travel burden, though in-person visits remain necessary for procedures like spirometry and blood draws.
Community health clinics and local chapters of the Asthma and Allergy Foundation of America sometimes serve as referral points for trial recruitment. Patient advocacy groups maintain lists of actively enrolling studies and can connect individuals with research coordinators who understand the nuances of "asthma clinical trial enrollment" in specific regions.
The decision to join a trial is deeply personal. It involves weighing the potential benefits of accessing a new treatment against the uncertainty inherent in research. A conversation with a pulmonologist or allergist—someone who knows your medical history and can speak to whether a particular study aligns with your asthma phenotype—is often the most practical starting point. From there, reaching out to a research coordinator at a nearby ACRC center or academic hospital can clarify what is available and whether it fits.
研究の知恵